Christer Halldin Selected Research

AZD3241

9/2015	Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease.
6/2015	Development of rapid multistep carbon-11 radiosynthesis of the myeloperoxidase inhibitor AZD3241 to assess brain exposure by PET microdosing.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christer Halldin Research Topics

Disease

27	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 01/2009
23	Schizophrenia (Dementia Praecox) 01/2022 - 01/2002
18	Parkinson Disease (Parkinson's Disease) 12/2020 - 10/2004
16	Mental Disorders (Mental Disorder) 01/2018 - 03/2002
13	Neuroinflammatory Diseases 01/2021 - 01/2009
10	Major Depressive Disorder (Major Depressive Disorders) 10/2021 - 11/2011
9	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 04/2008
9	Huntington Disease (Huntington's Disease) 01/2021 - 10/2011
4	Breast Neoplasms (Breast Cancer) 12/2022 - 06/2010
4	Stroke (Strokes) 04/2016 - 11/2002
4	Amyloid Plaque 09/2015 - 08/2010
3	Psychotic Disorders (Schizoaffective Disorder) 01/2022 - 01/2019
3	Disease Progression 01/2020 - 01/2012
3	Gliosis 03/2017 - 01/2011
3	Infarction (Infarctions) 04/2016 - 01/2012
2	Neoplasms (Cancer) 12/2021 - 01/2020
2	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2021 - 01/2008
2	Dyskinesias (Dyskinesia) 01/2019 - 10/2018
2	Hypersensitivity (Allergy) 01/2018 - 02/2011
2	Cognitive Dysfunction 01/2018 - 01/2016
2	Ischemic Stroke 04/2016 - 09/2012
2	Obesity 02/2016 - 03/2014
2	Mood Disorders (Mood Disorder) 02/2015 - 10/2013
2	Anxiety Disorders (Anxiety Disorder) 02/2014 - 11/2013
2	Nervous System Diseases (Neurological Disorders) 06/2013 - 01/2010
2	Multiple Sclerosis 04/2013 - 01/2008
2	Juvenile Myoclonic Epilepsy 02/2012 - 06/2005
2	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 09/2006 - 02/2005
2	Cerebrovascular Disorders (Cerebrovascular Occlusion) 11/2002 - 08/2002
1	Glioblastoma (Glioblastoma Multiforme) 12/2021
1	Ataxia Telangiectasia (Louis Bar Syndrome) 12/2021
1	Autistic Disorder (Autism) 01/2021

Drug/Important Bio-Agent (IBA)

18	Proteins (Proteins, Gene)FDA Link 12/2022 - 01/2009
15	Pharmaceutical PreparationsIBA 01/2020 - 01/2002
14	Dopamine (Intropin)FDA LinkGeneric 01/2022 - 05/2002
14	Serotonin (5 Hydroxytryptamine)IBA 01/2022 - 03/2002
14	Biomarkers (Surrogate Marker)IBA 08/2020 - 04/2008
11	Amyloid (Amyloid Fibrils)IBA 07/2019 - 11/2009
9	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 08/2020 - 09/2000
9	LigandsIBA 01/2020 - 01/2009
7	Dopamine Receptors (Dopamine Receptor)IBA 01/2020 - 05/2002
7	EnzymesIBA 01/2020 - 01/2011
6	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2020 - 06/2016
6	vinpocetineIBA 09/2012 - 08/2002
5	Antipsychotic Agents (Antipsychotics)IBA 01/2022 - 05/2002
5	Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA 10/2021 - 01/2003
5	5-HT1B Serotonin ReceptorIBA 01/2019 - 07/2008
5	RacloprideIBA 05/2012 - 02/2005
4	Monoamine Oxidase (MAO)IBA 12/2020 - 01/2011
4	Norepinephrine Plasma Membrane Transport Proteins (Norepinephrine Transporter)IBA 01/2019 - 09/2006
4	Amyloid beta-PeptidesIBA 01/2018 - 10/2010
3	5-HT1A Serotonin ReceptorIBA 01/2022 - 06/2005
3	GABA-A Receptors (GABA(A) Receptor)IBA 01/2021 - 01/2009
3	Neurotransmitter Agents (Neurotransmitter)IBA 03/2017 - 12/2014
3	2- (6- (methylamino)pyridin- 3- yl)- 1,3- benzothiazol- 6- olIBA 09/2015 - 11/2009
3	Cannabinoid Receptors (Cannabinoid Receptor)IBA 03/2014 - 02/2012
3	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 06/2013 - 06/2010
3	(R)- (11C)1- (2- chlorophenyl)- N- methyl- N- (1- methylpropyl)- 3- isoquinolinecarboxamideIBA 04/2013 - 01/2008
3	Peptides (Polypeptides)IBA 04/2012 - 01/2012
3	FLB 457IBA 12/2006 - 01/2002
3	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 12/2006 - 01/2002
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2022 - 11/2017
2	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/2021 - 10/2016
2	polyglutamineIBA 01/2021 - 01/2020
2	Metabotropic Glutamate 5 ReceptorIBA 01/2020 - 01/2018
2	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 01/2020 - 07/2019
2	Ketamine FDA LinkGeneric 01/2020 - 03/2015
2	Levodopa (L Dopa)FDA LinkGeneric 01/2019 - 10/2018
2	metabotropic glutamate receptor 4IBA 01/2019 - 10/2018
2	SCH 23390IBA 01/2019 - 05/2002
2	VortioxetineIBA 01/2019 - 10/2013
2	Antidepressive Agents (Antidepressants)IBA 01/2019 - 08/2008
2	Insulin (Novolin)FDA Link 12/2018 - 03/2015
2	Glutamic Acid (Glutamate)FDA Link 01/2018 - 02/2009
2	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2017 - 09/2015
2	AZD3241IBA 09/2015 - 06/2015
2	Peroxidase (Myeloperoxidase)IBA 09/2015 - 06/2015
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 03/2015 - 12/2014
2	Atomoxetine Hydrochloride (Strattera)FDA LinkGeneric 03/2015 - 09/2006
2	Quetiapine Fumarate (Seroquel)FDA Link 11/2013 - 11/2011
2	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 08/2013 - 09/2012
2	N- (5- fluoro- 2- phenoxyphenyl)- N- (2- fluoroethyl- 5- methoxybenzyl)acetamideIBA 06/2013 - 04/2013
2	4- cyano- 1- (2- iodophenyl)- 5- (4- methoxyphenyl)- N- (piperidin- 1- yl)- 1H- pyrazole- 3- carboxamideIBA 04/2012 - 02/2012
2	N- (3- iodoprop- 2- enyl)- 2- beta- carbomethoxy- 3- (4- methylphenyl)nortropaneIBA 02/2012 - 02/2005
2	Clozapine (Clozaril)FDA LinkGeneric 11/2011 - 03/2003
2	multidrug resistance-associated protein 1IBA 02/2011 - 06/2010
2	Biological ProductsIBA 03/2010 - 02/2008
1	Glycoproteins (Glycoprotein)IBA 12/2022
1	AZD1390IBA 12/2021
1	Protein Kinases (Protein Kinase)IBA 12/2021
1	Flumazenil (Romazicon)FDA LinkGeneric 01/2021
1	pyrimidineIBA 01/2021
1	Fluorine-18IBA 12/2020
1	Carbon-11IBA 12/2020
1	osimertinibIBA 01/2020
1	fenobamIBA 01/2020

Therapy/Procedure

4	Therapeutics 01/2017 - 01/2012
2	Aftercare (After-Treatment) 10/2021 - 09/2015
2	Oral Administration 03/2017 - 08/2002
1	Radiotherapy 12/2021